Table of Contents
ISRN Hematology
Volume 2012 (2012), Article ID 456706, 9 pages
http://dx.doi.org/10.5402/2012/456706
Review Article

18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma

1Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
2Division of Abdominal Imaging & Interventional Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

Received 8 December 2011; Accepted 29 December 2011

Academic Editors: S. Daenen, M. Gobbi, and S. Koschmieder

Copyright © 2012 M. J. Shelly et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional imaging afforded by FDG-PET/CT has led to superior sensitivity and specificity in the primary staging, restaging, and assessment of response to treatment of hematological malignancies when compared to FDG-PET and CT alone. The use of FDG-PET/CT for posttreatment surveillance imaging remains controversial, and further study is needed to ascertain whether this modality is cost effective and appropriate for use in this setting.